Mounjaro
(Tirzepatide)ApprovedPeptide
Eli LillyTirzepatide is used to help people with type 2 diabetes control their blood sugar levels, and it's also used for weight loss in people who are overweight or obese.[2] Mounjaro is currently approved and in use across 71 indications[4].[1]
Mounjaro is one of 1110 peptide programs targeting Intracranial Hypertension. It is currently in Approved.
71
Indications
202
Total Trials
130
Active Trials
1,109
Competitors
2
FDA Applications
NDA/BLA/ANDA regulatory filings
10
Patents
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 71 indications
Competition
Competitive Landscape
744 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Mounjaro
Eli LillyApproved
Adenocard
AstellasPreclinical
Zolymbus
AbbViePreclinical
Voltaren
NovartisPreclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Methylthioninium Chloride
PProvepharm SAS
Preclinical
Duragesic-100
CCephalon
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Cortef
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Acupan
YYonsei University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Q4 2026
Phase 1Recruiting
Type 2 Diabetes Mellitus
NCT07299084
Phase 2Active, not recruiting
Type 2 Diabetes
NCT06037252
Phase 1Recruiting
MASLD
NCT06934642
N/AActive, not recruiting
Cardiovascular Disease
NCT07303556
Phase 3Active, not recruiting
Type 1 Diabetes
NCT06914895
Phase 2Active, not recruiting
Long COVID
NCT07128082
Clinical
Trials by Indication[1]
Obesity37 trials
Semaglutide and Tirzepatide for Genetic Aging Delay in Adults With Obesity
Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·N/A·NCT07293325·66 enrolled
Show 34 more trials
Tirzepatide for Obesity and Meth Use Disorder
Active, not recruiting·UUniversity of Texas Southwestern Medical Center·Phase 2·NCT06745128·45 enrolled
Anti-obesity Pharmacotherapy and Inflammation
Active, not recruiting·LLouisiana State University Health Sciences Center in New Orleans··NCT05756764·30 enrolled
Effect of Semaglutide and Tirzepatide Combined With Exercise in Obesity
Not yet recruiting·—·N/A·NCT07319975·48 enrolled
An Open-Label Tirzepatide Trial for Comorbid Obesity and Stimulant Use Disorder Using fMRI to Identify Novel Neural Biomarkers
Enrolling by invitation·UUniversity of Texas Southwestern Medical Center·Phase 2·NCT07693608·45 enrolled
A Multicenter Randomized Controlled Trial Evaluating AI-Assisted Intensive Lifestyle Intervention Versus Tirzepatide for Glycemic and Weight Management in Patients With Obesity and Newly Diagnosed Type 2 Diabetes
Not yet recruiting·TThe First Affiliated Hospital of Anhui Medical University·Approved·NCT07697391·285 enrolled
Type 2 Diabetes26 trials
Show 23 more trials
Comparative Effectiveness of Tirzepatide vs Semaglutide in Participants With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction
Active, not recruiting·—··NCT06980623·26,000 enrolled
Overweight16 trials
Show 13 more trials
Type 2 Diabetes Mellitus8 trials
Show 5 more trials
Effectiveness and Safety of Tirzepatide Among Participants With Obesity With or Without Type 2 Diabetes Mellitus (T2DM)
Not yet recruiting·—··NCT07099742·364 enrolled
Type 1 Diabetes6 trials
82 more indications
ART4 trials
Show 1 more trial
Atrial Fibrillation3 trials
Endometrial Cancer3 trials
Psoriatic Arthritis3 trials
Obese3 trials
Can Fat-Burning Shots Boost Fertility? Comparing Weight-Loss Injections vs. Healthy Habits for Obese Men With Low Sperm Health
Not yet recruiting·FFirst Affiliated Hospital of Wenzhou Medical University·Phase 2·NCT07179120·180 enrolled
Heart Failure3 trials
Comparative Effectiveness of Tirzepatide Versus Semaglutide in Individuals With Heart Failure With Preserved Ejection Fraction
Completed·—··NCT06914141·28,118 enrolled
Emulation of the SUMMIT Heart Failure Trial in Healthcare Claims Data
Completed·—··NCT06914154·11,265 enrolled
Obesity and Overweight3 trials
Function2 trials
Breast Cancer2 trials
Tirzepatide Weight Loss for MRD+ Early Breast Cancer
Recruiting·—·Phase 2·NCT06517212·48 enrolled
GLP-12 trials
Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD
Recruiting·—··NCT07309094·250 enrolled
Cardiovascular2 trials
Prediction of the SURPASS-CVOT Cardiovascular Outcome Trial in Healthcare Claims Data
Completed·—··NCT07088718·44,671 enrolled
Comparative Effectiveness of Tirzepatide and Semaglutide in Individuals at Cardiovascular Risk
Completed·—··NCT07096063·887,132 enrolled
Cannabis Use Disorder2 trials
Tirzepatide for the Treatment of Cannabis Use Disorder
Not yet recruiting·—·Phase 2·NCT07265752·6 enrolled
Female2 trials
Diabetes Mellitus, Type 22 trials
Alcohol Use Disorder (AUD)2 trials
Effectiveness1 trial
Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes
Recruiting·TThe University of Texas Health Science Center at San Antonio·Phase 3·NCT06246799·256 enrolled
Adult1 trial
Effects of Tirzepatide on Muscle and Vascular Health in Obese Older Adults
Recruiting·TThe University of Texas Health Science Center at San Antonio·Phase 2·NCT06811324·20 enrolled
Colorectal Tumors1 trial
Hypertension1 trial
Semaglutide1 trial
DECODE - Haemodynamic Effects Of Semaglutide and Tirzepatide - a Series of Pilot Studies
Not yet recruiting·—·Phase 4·NCT07483801·112 enrolled
Metabolic Disease1 trial
Inflammatory Bowel Disease1 trial
Efficacy and Safety1 trial
Efficacy and Safety of Tirzepatide for Weight Management
Active, not recruiting·—·Phase 3·NCT06918405·440 enrolled
Hidradenitis Suppurativa1 trial
Evaluate the Efficacy of TIRZEPATIDE for the Treatment of Moderate to Severe HS Hidradenitis Suppurativa
Not yet recruiting·—·N/A·NCT06301256·20 enrolled
Schizophrenia1 trial
Cardiovascular Disease1 trial
Weight loss1 trial
Mortality1 trial
Obstructive Sleep Apnea1 trial
Prostate Cancer1 trial
Osteoarthritis1 trial
Coronary Atherosclerosis1 trial
Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT
Recruiting·—·Phase 4·NCT05708859·120 enrolled
Coronary Artery Disease1 trial
Body Weight1 trial
Motor Function1 trial
Methamphetamine Use Disorder1 trial
Randomized Controlled Trial of Tirzepatide for Methamphetamine Use Disorder
Not yet recruiting·UUniversity of Texas Southwestern Medical Center·Phase 2·NCT07825857·228 enrolled
Type 1 Diabetes Mellitus1 trial
Intracranial Hypertension1 trial
Metabolic Dysfunction-Associated Steatotic Liver Disease1 trial
Ulcerative Colitis1 trial
Diabetes Mellitus, Type 11 trial
Psoriasis1 trial
Obesity and Obesity-related Medical Conditions1 trial
Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia1 trial
Lung Cancer1 trial
Heart Failure, Diastolic1 trial
Prostate Carcinoma1 trial
Liver1 trial
A Randomized, Double-Blind, Placebo-Controlled, Flexible Dose Phase 2 Study of Efficacy and Safety of Tirzepatide in Individuals With Alcohol Use Disorder and Metabolic Alcohol-associated Liver Disease
Recruiting·NNational Institute on Alcohol Abuse and Alcoholism (NIAAA)·Phase 2·NCT07046819·120 enrolled
Opioid Use Disorder1 trial
Pouch, Ileal1 trial
Heart Failure and Reduced Ejection Fraction1 trial
Mild Autonomous Cortisol Secretion (MACS)1 trial
Acute Ischemic Stroke AIS1 trial
Human Immunodeficiency Virus (HIV)1 trial
Reversing the Biological Clock: Tirzepatide's Effects on Epigenetic Aging and Metabolic Restoration in Virally Suppressed People With HIV
Enrolling by invitation·NNational Taiwan University Clinical Trial Center·Approved·NCT07707778·60 enrolled
Neuropathy, Small Fiber1 trial
Effect of Tirzepatide on Diabetic Peripheral Sensorimotor Neuropathy: A Randomized, Open Label, Controlled Study
Not yet recruiting·PPost Graduate Institute of Medical Education and Research, Chandigarh·Approved·NCT07706088·40 enrolled
Steatosis1 trial
Hormone-receptor-positive Breast Cancer1 trial
Cannabis Use1 trial
Regulatory
FDA Approval Timeline[5]
Jul 28, 2023
MOUNJARO
NDA NDA215866
Mar 28, 2024
ZEPBOUND
NDA NDA217806
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Mounjaro drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Tirzepatide. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
- [7]
- [8]